protein

BCMA/TNFRSF17 Protein, Human (HEK293, mFc)

HY-P70827

10 μg;50 μg

130;390 USD

BCMA/TNFRSF17 Protein, Human (HEK293, mFc)

proteins

HEK293

10 μg;50 μg

130;390 USD

B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells [1] . BCMA/TNFRSF17 Protein, Human (HEK293, mFc) is a recombinant protein with a C-Terminal Fc label, It consists of 54 amino acids (M1-A54) and is produced in HEK293 cells.

Human

BCMA is expressed preferentially by mature B lymphocytes, with minimal expression in hematopoietic stem cells or nonhematopoietic tissue [1] . BCMA is almost exclusively expressed on plasmablasts and PCs [2] . The amino acid sequence of human BCMA protein has low homology for mouse BCMA protein. BCMA is a 184 amino acid and 20.2-kDa type III transmembrane glycoprotein, with the extracellular N terminus containing a conserved motif of 6 cysteines. BCMA has two agonist ligands: a proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF). Upon binding of the ligands to BCMA, activates B cells (NF-κβ), rat sarcoma/mitogen-activated protein kinase (RAS/MAPK), and phosphoinositide-3-kinase-protein kinase B/Akt (PI3K-PKB/Akt) signaling pathway. These pathways result in proliferation stimulation by modulating cell cycle checkpoints, increasing survival by upregulating anti-apoptotic proteins, and production of cell adhesion molecules, angiogenesis factors, and immunosuppressive molecules [2] . BCMA can be used as a promising antigen to target using a variety of immuno-therapy treatments including CART cells, for MM patients [3] . BCMA markedly reduces plasma IgA, IgG, and IgM levels and splenic Ig heavy chain mRNA levels in mouse [4] . In BCMA−/− mice, the long-term survival of PCs is impaired, but lack of BCMA has no effect in short-lived PCs, B cell development, or early humoral immune response, and the splenic architecture and germinal centers appear intact in these BCMA-deficient mice [5] . BCMA overexpression significantly promotes in vivo growth of xenografted MM cells in murine models [6] .

Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17; Bcm; Bcma

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Room temperature in continental US;may vary elsewhere.